3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
22
Breast Neoplasms
21
Polycystic Ovary Syndrome
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Lung Neoplasms
8
Endometrial Neoplasms
7
Pancreatic Neoplasms
6
Neoplasms
6
Glioblastoma
5
Rectal Neoplasms
4
Melanoma
4
Lymphoma, Large B-Cell, Diffuse
4
Insulin Resistance
4
Adenocarcinoma of Lung
4
Adenocarcinoma
4
Uterine Cervical Neoplasms
3
Leukoplakia, Oral
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Obesity
2
Neoplasm Metastasis
2
Liver Neoplasms
2
Leukemia, Myeloid, Acute
2
Hyperandrogenism
2
Esophageal Neoplasms
2
Erythroplasia
2
Endometrial Hyperplasia
2
Diabetes Mellitus
2
Colonic Neoplasms
2
Interventions
Cyclophosphamide
241
Rituximab
223
Etoposide
138
Filgrastim
113
Vincristine
112
Doxorubicin
104
Prednisone
90
Cytarabine
90
Methotrexate
79
fludarabine phosphate
77
Radiotherapy
76
Peripheral Blood Stem Cell Transplantation
71
Melphalan
71
Busulfan
60
Tacrolimus
48
Dexamethasone
48
Mycophenolic Acid
46
Carmustine
46
Granulocyte Colony-Stimulating Factor
44
fludarabine
43
Antilymphocyte Serum
40
Ifosfamide
38
sargramostim
34
Whole-Body Irradiation
34
Cyclosporine
33
Bortezomib
32
Gemcitabine
30
Methylprednisolone
27
Bendamustine Hydrochloride
27
Lenalidomide
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma
×
Metformin
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts